Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
Robert A. Burger(Mersana Therapeutics (United States)), Joel I. Sorosky(Penn State Milton S. Hershey Medical Center)
Cited by 880
Related Papers
American Society of Clinical Oncology Position Statement on Obesity and Cancer
|Journal of Clinical Oncology|2014|524